279 related articles for article (PubMed ID: 26463246)
21. The effect of neutralizing antibodies on the sustainable efficacy of biologic therapies: what's in it for African and Middle Eastern rheumatologists.
Alawadhi A; Alawneh K; Alzahrani ZA
Clin Rheumatol; 2012 Sep; 31(9):1281-7. PubMed ID: 22875700
[TBL] [Abstract][Full Text] [Related]
22. [Mechanism of action of biological disease--modifying antirheumatic drugs].
Takahashi N; Ishiguro N
Nihon Rinsho; 2016 Jun; 74(6):882-6. PubMed ID: 27311173
[No Abstract] [Full Text] [Related]
23. Reasons for Discontinuation and Adverse Effects of TNFα Inhibitors in a Cohort of Patients With Rheumatoid Arthritis and Ankylosing Spondylitis.
García-Lagunar MH; Gutiérrez-Cívicos MR; García-Simón MS; Conesa-Zamora P; Jimenez-Santos E; Cano-Vivar P; García-Márquez A; Muñoz-García I; Viney AC
Ann Pharmacother; 2017 May; 51(5):388-393. PubMed ID: 27920336
[TBL] [Abstract][Full Text] [Related]
24. Indirect comparisons of the efficacy of subsequent biological agents in patients with psoriatic arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysis.
Ungprasert P; Thongprayoon C; Davis JM
Clin Rheumatol; 2016 Jul; 35(7):1795-803. PubMed ID: 26852316
[TBL] [Abstract][Full Text] [Related]
25. [Recombinant proteins or monoclonal antibodies: comparative properties and interest in rheumatoid arthritis].
Sibilia J
Med Sci (Paris); 2009 Dec; 25(12):1033-8. PubMed ID: 20035675
[TBL] [Abstract][Full Text] [Related]
26. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
[TBL] [Abstract][Full Text] [Related]
27. Emerging therapeutics for rheumatoid arthritis.
Bingham CO
Bull NYU Hosp Jt Dis; 2008; 66(3):210-5. PubMed ID: 18937634
[TBL] [Abstract][Full Text] [Related]
28. [Biologic therapy of rheumatoid arthritis].
Damjanov N; Vojinović J
Srp Arh Celok Lek; 2009; 137(3-4):205-10. PubMed ID: 19459571
[TBL] [Abstract][Full Text] [Related]
29. Differential effects of biological DMARDs on peripheral immune cell phenotypes in patients with rheumatoid arthritis.
Nakayamada S; Kubo S; Yoshikawa M; Miyazaki Y; Yunoue N; Iwata S; Miyagawa I; Hirata S; Nakano K; Saito K; Tanaka Y
Rheumatology (Oxford); 2018 Jan; 57(1):164-174. PubMed ID: 28371836
[TBL] [Abstract][Full Text] [Related]
30. Safety of anti-tumor necrosis factor therapies in arthritis patients.
Nanau RM; Neuman MG
J Pharm Pharm Sci; 2014; 17(3):324-61. PubMed ID: 25224347
[TBL] [Abstract][Full Text] [Related]
31. Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.
Favalli EG; Sinigaglia L; Becciolini A; Grosso V; Gorla R; Bazzani C; Atzeni F; Sarzi Puttini PC; Fusaro E; Pellerito R; Caporali R
Int J Rheum Dis; 2018 Feb; 21(2):422-430. PubMed ID: 29082659
[TBL] [Abstract][Full Text] [Related]
32. Biologic therapies and bone loss in rheumatoid arthritis.
Zerbini CAF; Clark P; Mendez-Sanchez L; Pereira RMR; Messina OD; Uña CR; Adachi JD; Lems WF; Cooper C; Lane NE;
Osteoporos Int; 2017 Feb; 28(2):429-446. PubMed ID: 27796445
[TBL] [Abstract][Full Text] [Related]
33. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
[TBL] [Abstract][Full Text] [Related]
34. Safety issues and concerns of new immunomodulators in rheumatology.
Selmi C; Ceribelli A; Naguwa SM; Cantarini L; Shoenfeld Y
Expert Opin Drug Saf; 2015 Mar; 14(3):389-99. PubMed ID: 25518908
[TBL] [Abstract][Full Text] [Related]
35. Biologic Therapy in Psoriasis (Part I): Efficacy and Safety of Tumor Necrosis Factor- α Inhibitors.
Campanati A; Molinelli E; Brisigotti V; Offidani A
Curr Pharm Biotechnol; 2017; 18(12):945-963. PubMed ID: 29424306
[TBL] [Abstract][Full Text] [Related]
36. [Diagnosis and treatment of rheumatoid arthritis:toward the best practice. The best practice for TNF inhibitors.].
Kameda H
Clin Calcium; 2018; 28(5):655-660. PubMed ID: 29731461
[TBL] [Abstract][Full Text] [Related]
37. Biologic Therapy in Psoriasis: Safety Profile.
Campanati A; Ganzetti G; Giuliodori K; Molinelli E; Offidani A
Curr Drug Saf; 2016; 11(1):4-11. PubMed ID: 26463245
[TBL] [Abstract][Full Text] [Related]
38. [Anti-TNF alpha in the treatment of rheumatoid arthritis and ankylosing spondylitis].
Lanfant-Weybel K; Lequerré T; Vittecoq O
Presse Med; 2009 May; 38(5):774-87. PubMed ID: 19327945
[TBL] [Abstract][Full Text] [Related]
39. The risk of infections with biologic therapies for rheumatoid arthritis.
Furst DE
Semin Arthritis Rheum; 2010 Apr; 39(5):327-46. PubMed ID: 19117595
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness simulation model of biologic strategies for treating to target rheumatoid arthritis in Germany.
Beresniak A; Baerwald C; Zeidler H; Krüger K; Neubauer AS; Dupont D; Merkesdal S
Clin Exp Rheumatol; 2013; 31(3):400-8. PubMed ID: 23464803
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]